Alkem Laboratories Limited has informed the Exchange about Amendment(s)
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories has signed an Amendment cum Supplemental Agreement dated 13th February, 2026 with its subsidiary Enzene Biosciences, existing PE investors Eight Roads Ventures and F-Prime Capital, and a new investor ERVI Healthcare. The amendment allows F-Prime Capital and ERVI Healthcare to collectively invest around Rs. 26.16 crore in Enzene by subscribing to 5,58,302 Series B Compulsorily Convertible Preference Shares (CCPS) and 10 equity shares at Rs. 468.60 per share on a preferential basis. Post-allotment, Alkem will hold 88.99% of Enzene on a fully diluted basis, while Eight Roads holds 5.42%, F-Prime 1.87%, and ERVI Healthcare 0.71%. ERVI Healthcare is also being added as a party to the original 2022 Shareholders' Agreement. The transaction is not a related-party transaction and there is no impact on Alkem's management or control.
This is a capital infusion into Alkem's subsidiary Enzene by existing and new PE investors, which is a routine portfolio-level development. Alkem retains majority control of Enzene at nearly 89%, so there is no meaningful change in ownership or control for Alkem shareholders.